Clinuvel Pharmaceuticals
(OTC) CLVLY
Clinuvel Pharmaceuticals Financials at a Glance
Market Cap
$340.50M
Revenue (TTM)
$186.65M
Net Income (TTM)
$71.12M
EPS (TTM)
$0.41
P/E Ratio
16.30
Dividend
$0.03
Beta (Volatility)
0.69 (Low)
Dividend
$0.03
Beta (Volatility)
0.69 (Low)
Price
$6.79
Volume
1,251
Open
$6.75
Price
$6.79
Volume
1,251
Open
$6.75
Previous Close
$6.79
Daily Range
$6.75 - $6.79
52-Week Range
$6.00 - $9.00
Dividend
$0.03
Beta (Volatility)
0.69 (Low)
Price
$6.79
Volume
1,251
Open
$6.75
Previous Close
$6.79
Daily Range
$6.75 - $6.79
52-Week Range
$6.00 - $9.00
CLVLY News
CLVLY: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Clinuvel Pharmaceuticals
Industry
Biotechnology
Sector
Health CareCEO
Lachlan Hay
Website
www.clinuvel.comHeadquarters
Melbourne, VIC 3000, AU
CLVLY Financials
Key Financial Metrics (TTM)
Gross Margin
64%
Operating Margin
39%
Net Income Margin
34%
Return on Equity
14%
Return on Capital
15%
Return on Assets
12%
Earnings Yield
6.13%
Dividend Yield
0.00%
Payout Ratio
7.70%
Stock Overview
Market Cap
$340.50M
Shares Outstanding
50.18M
Volume
1.25K
Short Interest
0.00%
Avg. Volume
2.76K
Financials (TTM)
Gross Profit
$79.14M
Operating Income
$45.73M
EBITDA
$57.20M
Operating Cash Flow
$41.10M
Capital Expenditure
$298.57K
Free Cash Flow
$40.80M
Cash & ST Invst.
$224.11M
Total Debt
$528.53K
Clinuvel Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$36.25M
+12.4%
Gross Profit
$20.37M
+20.4%
Gross Margin
56.19%
N/A
Market Cap
$340.50M
N/A
Market Cap/Employee
N/A
N/A
Employees
N/A
N/A
Net Income
$10.25M
-6.3%
EBITDA
$11.25M
-22.3%
Quarterly Fundamentals
Net Cash
$232.43M
+34.1%
Accounts Receivable
$16.57M
+26.7%
Inventory
$8.40M
-33.1%
Long Term Debt
$34.46K
-95.2%
Short Term Debt
$306.29K
-13.9%
Return on Assets
12.07%
N/A
Return on Invested Capital
15.06%
N/A
Free Cash Flow
$12.15M
-42.4%
Operating Cash Flow
$12.30M
-53.4%